Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

NCT01568021 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT01568021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01568021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
Lead sponsor
Allergan
Phase
Observational
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2013
Enrollment
100 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema, retinal vein occlusion